Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (27430)	1/16/1999 11:14:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

TD, Time frames are very fuzzy to me. I have not been able to get any useful info from LGND IR for several months now. Cancer, psoriasis, and diabetes clinicals were supposed to be release by the end of last year (actually some of the cancer clinicals were supposed to have been released by the end of 1997), and final FDA approvals (on ONTAK and topical Panretin) were possible by the end of last year. I would assume that all of the above would come out soon, but I've thought that about the clinicals for well over a year now. It's my understanding that NDA filings for topical and oral Targretin (for CTCL) are slated for this year (topical soon and oral to follow topical). MMA's for Panretin in Europe should be filed soon also. Diabetes clinicals in the US are slated for some time this year, but I expected them to start last year. I believe that the initial breast cancer Phase II data is slated for 3Q. I suspect that LGND will also be announcing product or company acquisitions this year. I have to get a more detailed H&Q update to come up with some harder dates (although dates have been rather soft for some time now).